Physician profile
Bridget E Cervantes
NPI 1871264366
$3,736.56
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $2,243 · 2023: $1,191 · 2024: $20.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,066.42 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,038.61 | 2021-2023 | Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $220.86 | 2022 | |
| Janssen Biotech, INC. | $182.56 | 2022-2023 | Stelara |
| Intercept Pharmaceuticals, INC. | $179.45 | 2022-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.62 | 2022-2023 | Xifaxan |
| Genzyme Corporation | $149.57 | 2022-2023 | |
| Celgene Corporation | $106.35 | 2022-2023 | Zeposia |
| Organon LLC | $74.17 | 2022-2023 | Hadlima |
| Ferring Pharmaceuticals INC. | $71.10 | 2022-2023 | Rebyota, Clenpiq |
| Ardelyx, INC. | $67.88 | 2022-2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $63.74 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $56.77 | 2022-2023 | Dupixent |
| Gilead Sciences, INC. | $56.40 | 2021-2022 | |
| Redhill Biopharma INC. | $42.58 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oxford Immunotec USA INC | $38.78 | 2022 | |
| Merck Sharp & Dohme LLC | $38.34 | 2022 | |
| Fresenius Kabi USA, LLC | $25.05 | 2023 | Idacio |
| Digestive Care, INC. | $24.57 | 2023 | Pertzye |
| Mylan Institutional INC. | $23.35 | 2023 | Hulio |
| Aimmune Therapeutics, INC. | $20.84 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.55 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Cervantes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.